🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression

Recruitingn/aAges 40 Years - 90 YearsAllCentervue SpA
NCT05801471 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Glaucomatous optic nerve head in both eyes; * Age between 40 and 90 years; * Best Corrected Visual Acuity ≤ 0.3 \[logMar\]; * Spherical refraction between -6D and +6D; * Astigmatism between -2D and +2D. Exclusion Criteria: * Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment; * Any ocular pathology that can affect visual field other than glaucoma; * Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss; * Inability to obtain reliable perimetric examinations; * Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.
💊

What it tests

  • Not listed
📍

Where

2 sites
Clinica oculistica Ospedale San Paolo
Milan, Italy
Glaucoma Research Center, IRCCS Fondazione "G.B. Bietti"
Roma, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy